Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Susan C Modesitt

Phase 1–2 Study of Docetaxel Plus Aflibercept in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

The Lancet Oncology

Oncology

2011

English

Related publications

Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

English

A Phase II Study of the Combination Chemotherapy of Bevacizumab and Gemcitabine in Women With Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Journal of Ovarian Research

English

Erratum To: The New WHO Classification of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer and Its Clinical Implications

Archives of Gynecology and Obstetrics

English

Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

Urology

2010

English

Follow-Up of Patients Who Are Clinically Disease-Free After Primary Treatment for Fallopian Tube, Primary Peritoneal, or Epithelial Ovarian Cancer: A Program in Evidence-Based Care Guideline Adaptation

Current Oncology

Oncology

2016

English

Ovarian Cancer May Originate in the Fallopian Tube

Cancer Discovery

Oncology

2012

English

Phase II Evaluation of Dasatinib in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

English

Salpingo-Oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation

JAMA - Journal of the American Medical Association

Medicine

2006

English

A Phase II Evaluation of Lapatinib in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Susan C Modesitt

Phase 1–2 Study of Docetaxel Plus Aflibercept in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Related publications

Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

A Phase II Study of the Combination Chemotherapy of Bevacizumab and Gemcitabine in Women With Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Erratum To: The New WHO Classification of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer and Its Clinical Implications

Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

Follow-Up of Patients Who Are Clinically Disease-Free After Primary Treatment for Fallopian Tube, Primary Peritoneal, or Epithelial Ovarian Cancer: A Program in Evidence-Based Care Guideline Adaptation

Ovarian Cancer May Originate in the Fallopian Tube

Phase II Evaluation of Dasatinib in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

Salpingo-Oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation

A Phase II Evaluation of Lapatinib in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study